ArticleDiscover oncology2025
Timosaponin B-II suppresses gastric cancer cell proliferation and induces apoptosis via the Nrf2/miR-455-3p/KLF6 pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Timosaponin B-II attenuates hemorrhagic transformation-driven acceleration of alzheimer disease-related pathology after ischemic stroke.Biochemistry and biophysics reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGastric cancer (GC), known for its aggressive growth and metastasis, remains a leading cause of cancer-related mortality. Although Timosaponin B-II (TB-II) from Anemarrhena asphodeloides has shown anticancer potential, its underlying mechanisms in GC are not yet fully understood.
methodsOur study investigates and compares the expression patterns of Kruppel-Like Factor 6(KLF6) in GC tissues across different TNM stages, while exploring its upstream regulatory factors. GC cells were treated with Timosaponin B-II (TB-II), and alterations in cell proliferation and apoptosis rates were evaluated using CCK-8 and TUNEL assays. Furthermore, the expression levels of nuclear factor erythroid 2-related factor 2(Nrf2), miR-455-3p, and KLF6 were quantified to elucidate the mechanisms underlying TB-II's effects. To confirm the interaction between miR-455-3p and KLF6, as well as Nrf2 and miR-455-3p, bioinformatics analysis, luciferase assays, and ChIP-PCR were conducted. Finally, protein synthesis and degradation assays were performed to explore the mechanism by which TB-II regulates the expression and activity of Nrf2.
resultsBoth mRNA and protein expression levels of KLF6 were significantly lower in GC tissues compared to adjacent normal tissues. Notably, only KLF6 protein expression exhibited a decline in GC tissues from stages I to III of GC, whereas its upstream regulator, miR-455-3p, displayed the opposite trend. Treatment with TB-II markedly inhibited GC cells proliferation and induced apoptosis in a dose-dependent manner. Mechanistically, TB-II treatment upregulated the expression of Kelch-like ECH-associated protein 1(Keap1) protein, facilitating the formation of the Keap1/Nrf2 complex, which enhanced the ubiquitin-mediated degradation of Nrf2 in GC cells. Consequently, the transcriptional activation of miR-455-3p by Nrf2 was suppressed, resulting in the upregulation of the tumor suppressor KLF6. Silencing KLF6 can counteract the effects of TB-II in inhibiting proliferation and promoting apoptosis in GC cells.
conclusionTB-II suppresses GC cell proliferation and induces apoptosis via the Nrf2/miR-455-3p/KLF6 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.